PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsVilazodone
Vilazodone
Viibryd, Vilazodone (vilazodone) is a small molecule pharmaceutical. Vilazodone was first approved as Viibryd on 2011-01-21. It is used to treat major depressive disorder in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and 5-hydroxytryptamine receptor 1A. In addition, it is known to target histamine H1 receptor, D(3) dopamine receptor, D(2) dopamine receptor, and 5-hydroxytryptamine receptor 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
Viibryd, Vilazodone
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Vilazodone hydrochloride
Tradename
Company
Number
Date
Products
VIIBRYDAbbVieN-022567 RX2011-01-21
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
viibrydNew Drug Application2023-10-17
vilazodoneNDA authorized generic2024-06-05
vilazodone hydrochlorideANDA2025-08-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
major depressive disorderEFO_0003761D003865F22
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06A: Antidepressants
— N06AX: Other antidepressants in atc
— N06AX24: Vilazodone
HCPCS
No data
Clinical
Clinical Trials
34 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863—F33.9—597—21
Major depressive disorderD003865EFO_0003761F22—497—20
Depressive disorderD003866EFO_1002014F32.A—497—20
Anxiety disordersD001008EFO_0006788F41.1——3115
Post-traumatic stress disordersD013313EFO_0001358F43.1—2—1—3
Physiological sexual dysfunctionD012735—————1—1
MorbidityD009017—————1—1
AnxietyD001007EFO_0005230F41.1———1—1
Separation anxietyD001010EFO_1001916————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Generalized anxiety disorderD000098647————3——3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Memory disordersD008569———1———1
Marijuana abuseD002189EFO_0007191F12—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bipolar disorderD001714EFO_0000289F30.9————11
Social phobiaD000072861EFO_1001917F40.1————11
Hot flashesD019584——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVilazodone
INNvilazodone
Description
Vilazodone is a 1-benzofuran that is 5-(piperazin-1-yl}-1-benzofuran-2-carboxamide having a (5-cyanoindol-3-yl)butyl group attached at position N-4 on the piperazine ring. Used for the treatment of major depressive disorder. It has a role as an antidepressant, a serotonergic agonist and a serotonin uptake inhibitor. It is a member of indoles, a nitrile, a N-arylpiperazine, a N-alkylpiperazine, a member of 1-benzofurans and a monocarboxylic acid amide. It is a conjugate base of a vilazodone(1+).
Classification
Small molecule
Drug classSerotonin modulator
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1
Identifiers
PDB—
CAS-ID163521-12-8
RxCUI—
ChEMBL IDCHEMBL439849
ChEBI ID70707
PubChem CID6918314
DrugBankDB06684
UNII IDS239O2OOV3 (ChemIDplus, GSRS)
Target
Agency Approved
SLC6A4
SLC6A4
HTR1A
HTR1A
Organism
Homo sapiens
Gene name
SLC6A4
Gene synonyms
HTT, SERT
NCBI Gene ID
6532
Protein name
sodium-dependent serotonin transporter
Protein synonyms
5-hydroxytryptamine (serotonin) transporter, 5HT transporter, 5HTT, Na+/Cl- dependent serotonin transporter, serotonin transporter 1, solute carrier family 6 (neurotransmitter transporter), member 4, solute carrier family 6 (neurotransmitter transporter, serotonin), member 4, Solute carrier family 6 member 4
Uniprot ID
Q5EE02
Mouse ortholog
Slc6a4 (15567)
sodium-dependent serotonin transporter (Q60857)
Alternate
HRH1
HRH1
DRD3
DRD3
DRD2
DRD2
HTR4
HTR4
Organism
Homo sapiens
Gene name
HRH1
Gene synonyms
NCBI Gene ID
3269
Protein name
histamine H1 receptor
Protein synonyms
histamine receptor, subclass H1
Uniprot ID
Q6P9E5
Mouse ortholog
Hrh1 (15465)
histamine H1 receptor (Q91XN3)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Vilazodone
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,130 documents
View more details
Safety
Black-box Warning
Black-box warning for: Viibryd, Vilazodone, Vilazodone hydrochloride
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,960 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use